Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01531140
Other study ID # 1/2012
Secondary ID
Status Completed
Phase Phase 4
First received January 16, 2012
Last updated February 9, 2012
Start date November 2010
Est. completion date November 2011

Study information

Verified date January 2012
Source Medical University of Warsaw
Contact n/a
Is FDA regulated No
Health authority Poland: Ministry of Science and Higher Education
Study type Interventional

Clinical Trial Summary

Background:

Polyethylene glycol (PEG) solution has been proven to be effective for large bowel cleansing prior to colonoscopy in children. However, the high volume of fluid and its taste sometimes lead to inappropriate cleansing of the bowel, thus search for other bowel preparation is needed.

Aim:

The efficacy and tolerability of three different bowel cleansing protocols used in children for colonoscopy: high-volume PEG compared with low-volume PEG with stimulant laxative (bisacodyl) compared with sennosides.

Methods:

Participants aged 10-18 years will be randomly assigned to receive either PEG 60 ml/kg/day or PEG 30 ml/kg/day plus oral bisacodyl 10-15 mg/day or sennosides 2mg/kg/day for 2 days prior to the colonoscopy. The outcome measures will be:bowel cleansing efficacy, scored by a blinded endoscopist using the Ottawa scale and Aronchick Scale (the mean total score, proportions of participants with excellent/good and with poor/inadequate bowel preparation), and the patient satisfaction score(0-10)with the method of preparation for the colonoscopy evaluated with the visual analog scale. Analysis will be done on an intention to treat basis.


Description:

Patients are excluded if they had known allergy to one of the tested preparations such as bisacodyl (Bisacodyl VP, ICN Polfa, Rzeszow, Poland), polyethylene glycol (Fortrans, Beaufour Ipsen Industry, Dreux, France) and/or sennoside (Xenna Extra, US Pharmacia, Wroclaw, Poland) and had disorders that make oral intake of the preparation impossible (neurological disorders, intestinal obstruction, mental retardation etc.).

Study design:

On admission day patients are allocated to one of the groups by study investigators, according to the randomization list created by an independent person using block randomization by a standard statistical program StatsDirect [version 2,3,8 (2005)] (6 patients were included in each block).

During the preparation for colonoscopy each patient are observed for procedure tolerance. On the day of endoscopy, each patient evaluated the degree of the acceptance of the method of bowel cleaning (according to visual analog scale (VAS) and the occurrence of side effects (diary). The endoscopist performing colonoscopy, blinded for the bowel preparation regimen evaluate bowel cleansing and score it, according to the Aronchick and Ottawa scale. The rate of cecum intubation, and the colonoscopy complications (defined as bowel perforation and/or significant bleeding) are analyzed in each bowel preparation group.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 10 Years to 18 Years
Eligibility Inclusion Criteria:

- children 10 - 18 years of age referred for colonoscopy

- informed consent signed

Exclusion Criteria:

- allergy to PEG, sennosides or bisacodyl

- disorders that make oral intake of the preparation impossible (neurological disorders, intestinal obstruction, mental retardation etc.)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
polyethylene glycol +Bisacodyl
Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
Polyethylene glycol
Polyethylene glycol p.o.: 60 ml/kg/days
Sennosides
Sennosides 1tbl/8kg for 2 days

Locations

Country Name City State
Poland Child Health Center Warsaw
Poland Warsaw Medical University Warsaw

Sponsors (2)

Lead Sponsor Collaborator
Medical University of Warsaw Institute of Child Health

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary proportions of participants with good or excellent bowel preparation assessed with Ottawa Scale According to the Ottawa scale the quality of bowel preparation is estimated by adding points for the cleansing of three parts of colon (descending, transversal and ascending) and points for amount of fluid in the bowel. Score: 0-1 - excellent cleansing, 2-4 - good, 5-7 - sufficient, 8-10 - poor, 11-14 - not appropriate. bowel preparation quality with Ottawa scale is assesed during colonoscopy (3rd day of the study) by endoscopist blinded for the method of preparation No
Primary proportions of participants with poor/inadequate bowel preparation assessed with Ottawa Scale According to the Ottawa scale the quality of bowel preparation is estimated by adding points for the cleansing of three parts of colon (descending, transversal and ascending) and points for amount of fluid in the bowel. Score: 0-1 - excellent cleansing, 2-4 - good, 5-7 - sufficient, 8-10 - poor, 11-14 - not appropriate. bowel preparation quality with Ottawa scale is assesed during colonoscopy (3rd day of the study) by endoscopist blinded for the method of preparation No
Secondary proportions of participants with very good/good bowel preparation assessed with Aronchick Scale According to Aronchick scale preparation is estimated as:
very good: small amount of clear fluid is present, more than 95% mucosa is visible
good: small amount of clear fluid easy to suction away or flush is present, more than 90% of mucosa is visible
sufficient: big amount of clear fluid covering 5-25% of mucosa, more than 90% of mucosa visible
poor: semi-liquid stool that cannot be flushed, less than 90% of mucosa visible
inadequate: colonoscopy must be repeated
bowel preparation quality with Aronchick scale is assesed during colonoscopy (3rd day of the study) by endoscopist blinded for the method of preparation No
Secondary proportions of participants with poor/inadequate bowel preparation assessed with Aronchick Scale According to Aronchick scale preparation is estimated as:
very good: small amount of clear fluid is present, more than 95% mucosa is visible
good: small amount of clear fluid easy to suction away or flush is present, more than 90% of mucosa is visible
sufficient: big amount of clear fluid covering 5-25% of mucosa, more than 90% of mucosa visible
poor: semi-liquid stool that cannot be flushed, less than 90% of mucosa visible
inadequate: colonoscopy must be repeated
bowel preparation quality with Aronchick scale is assesed during colonoscopy (3rd day of the study) by endoscopist blinded for the method of preparation No
Secondary mean bowel preparation score assessed with Ottawa Scale According to the Ottawa scale the quality of bowel preparation is estimated by adding points for the cleansing of three parts of colon (descending, transversal and ascending) and points for amount of fluid in the bowel. Score: 0-1 - excellent cleansing, 2-4 - good, 5-7 - sufficient, 8-10 - poor, 11-14 - not appropriate. bowel preparation quality with Ottawa scale is assesed during colonoscopy (3rd day of the study) by endoscopist blinded for the method of preparation No
Secondary mean bowel preparation score assessed with Aronchick scale According to Aronchick scale preparation is estimated as:
very good: small amount of clear fluid is present, more than 95% mucosa is visible
good: small amount of clear fluid easy to suction away or flush is present, more than 90% of mucosa is visible
sufficient: big amount of clear fluid covering 5-25% of mucosa, more than 90% of mucosa visible
poor: semi-liquid stool that cannot be flushed, less than 90% of mucosa visible
inadequate: colonoscopy must be repeated
bowel preparation quality with Aronchick scale is assesed during colonoscopy (3rd day of the study) by endoscopist blinded for the method of preparation No
Secondary patient satisfaction with the method of preparation assessed with Visual analogue scale (VAS) VAS scale is horizontal line 100 mm lenght anchored by word description at each end (very good, very bad).The patient mark on the line the point that feel represent the perception of bowel preparation regimen. assessed by patient after completion of bowel preparation regimen before colonoscopy (3rd day of the study) No
See also
  Status Clinical Trial Phase
Terminated NCT01140295 - Bowel Preparation for Colonoscopy in Children Phase 4
Recruiting NCT03290157 - Improvement of Colonoscopy Preparation by Using a SPA N/A
Completed NCT04150133 - Effects and Tolerability With Clenpiq and Low Residue Diet N/A
Completed NCT06021639 - Comparison of Bowel Cleansing Regimens for Colonoscopy N/A
Completed NCT02073552 - Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid. Phase 4
Completed NCT01596686 - Comparison of Preparation Regimens for Colonoscopy N/A
Withdrawn NCT04361656 - The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation
Completed NCT01610856 - Single Dose Versus Split Dose Polyethylene Glycol-based Colonic Lavage for Colonoscopy N/A
Completed NCT02410720 - The Effectiveness of a Customized Mobile Application in Colonoscopy Preparation N/A
Completed NCT01887470 - 2 Regimens of Lactulose for Colonoscopy Preparation in Adults Phase 2
Completed NCT06282367 - Bowel Preparation for Colonoscopy With Oral Lactulose
Completed NCT02304523 - Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy Phase 3
Completed NCT06453655 - The Effect of Nurse Process on Bowel Cleansing N/A
Completed NCT02665624 - Adding Stewed Apricot Juice to Senna Improves the Right-Side and Overall Colon Cleansing Quality for Colonoscopy Preparation Phase 4
Completed NCT02123017 - Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy Phase 2